During the past decade, Seconda Università degli Studi di Napoli conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 10 clinical trials were completed, i.e. on average, 90.9% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 6 clinical trials were completed. i.e. 600% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Seconda Università degli Studi di Napoli" #1 sponsor was "EMD Serono Research & Development Institute, Inc." with 4 trials, followed by "Biogen" with 2 trials sponsored, "Amgen" with 1 trials sponsored, "Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari" with 1 trials sponsored and "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Seconda Università degli Studi di Napoli" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Seconda Università degli Studi di Napoli" are "Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification" (1 trials), "Advanced Colorectal Cancer" (1 trials), "Alzheimer's Disease" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials) and "Chronic Hepatitis B" (1 trials). Many other conditions were trialed in "Seconda Università degli Studi di Napoli" in a lesser frequency.

Most popular intervention types in "Seconda Università degli Studi di Napoli" are "Drug" (12 trials), "Other" (3 trials), "Biological" (1 trials), "Dietary Supplement" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Avelumab" (3 trials), "Placebo" (3 trials), "Capecitabine" (2 trials), "5-Fluorouracil" (1 trials) and "Adalimumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Seconda Università degli Studi di Napoli" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Seconda Università degli Studi di Napoli". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Seconda Università degli Studi di Napoli, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Seconda Università degli Studi di Napoli, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".